Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong · Delayed Price · Currency is HKD 3.290
+0.060 (1.86%)
Feb 13, 2026, 4:08 PM HKT
HKG:1349 Revenue
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had revenue of 160.99M CNY in the quarter ending September 30, 2025, with 14.40% growth. This brings the company's revenue in the last twelve months to 711.63M, up 2.89% year-over-year. In the year 2024, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had annual revenue of 709.40M, down -16.61%.
Revenue (ttm)
711.63M CNY
Revenue Growth
+2.89%
P/S Ratio
10.29
Revenue / Employee
791.58K CNY
Employees
899
Market Cap
8.00B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 709.40M | -141.33M | -16.61% |
| Dec 31, 2023 | 850.73M | -180.43M | -17.50% |
| Dec 31, 2022 | 1.03B | -109.15M | -9.57% |
| Dec 31, 2021 | 1.14B | 306.51M | 36.76% |
| Dec 31, 2020 | 833.80M | -195.49M | -18.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition